Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $62.8 million.

  • Cytosorbents' Shares Outstanding (Weighted Average) rose 1524.43% to $62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.8 million, marking a year-over-year increase of 1524.43%. This contributed to the annual value of $54.4 million for FY2024, which is 2189.66% up from last year.
  • Latest data reveals that Cytosorbents reported Shares Outstanding (Weighted Average) of $62.8 million as of Q3 2025, which was up 1524.43% from $62.6 million recorded in Q2 2025.
  • Cytosorbents' Shares Outstanding (Weighted Average)'s 5-year high stood at $62.8 million during Q3 2025, with a 5-year trough of $43.2 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $44.0 million (2023), whereas its average is $48.8 million.
  • Per our database at Business Quant, Cytosorbents' Shares Outstanding (Weighted Average) surged by 2725.48% in 2021 and then surged by 43.34% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Shares Outstanding (Weighted Average) stood at $43.4 million in 2021, then increased by 0.49% to $43.6 million in 2022, then grew by 2.49% to $44.7 million in 2023, then increased by 21.9% to $54.4 million in 2024, then increased by 15.28% to $62.8 million in 2025.
  • Its last three reported values are $62.8 million in Q3 2025, $62.6 million for Q2 2025, and $60.7 million during Q1 2025.